BrainsWay Ltd. (BWAY)

BrainsWay shares surge after the FDA cleared its accelerated Deep TMS protocol, offering faster depression treatment with strong clinical results.

BrainsWay's $5 million investment in Neurolief expands its mental health footprint with at-home depression treatment potential.

This investment marks BrainsWay's entrance into the market for mental health therapies that can be administered outside of a clinic, including at home

The Investment is part of BrainsWay's ongoing strategy to acquire minority positions in leading U.S. mental health providers to help them raise awareness for and expand access to transformative care The Investment is part of BrainsWay's ongoing strategy to acquire minority positions in leading U.S. mental health providers to help them raise awareness for and expand access to transformative care

Brainsway (BWAY) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Brainsway Ltd. Sponsored ADR (BWAY) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

The mean of analysts' price targets for Brainsway (BWAY) points to a 25.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

BrainsWay Ltd. (NASDAQ:BWAY ) Q2 2025 Earnings Conference Call August 13, 2025 8:30 AM ET Company Participants Hadar Levy - Chief Executive Officer Ido Marom - Chief Financial Officer Conference Call Participants Carl Edward Byrnes - Northland Capital Markets, Research Division Jeffrey Scott Cohen - Ladenburg Thalmann & Co. Inc., Research Division Garth Russell - Unidentified Company Operator Good day, and welcome to the BrainsWay Second Quarter 2025 Earnings Conference Call.

Achieved record quarterly revenue of $12.6 million in Q2 2025, an increase of 26% compared to Q2 2024 Operating profit totaled $0.6 million and Adjusted EBITDA rose to $1.5 million, Raised full-year 2025 Revenue and EBITDA guidance Remaining performance obligations increased by 25% YOY to $62 million Conference call to be held today at 8:30 AM ET BURLINGTON, Mass. and JERUSALEM, Aug. 13, 2025 (GLOBE NEWSWIRE) -- BrainsWay Ltd.

Let's take a look at four stocks, CPRX, GAMB, ORN and BWAY, with stellar net profit margins and rising EPS estimates that can help create a winning portfolio.

Investors need to pay close attention to Brainsway stock based on the movements in the options market lately.

The mean of analysts' price targets for Brainsway (BWAY) points to a 31% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Brainsway (BWAY) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

Here is how Brainsway Ltd. Sponsored ADR (BWAY) and Cardinal Health (CAH) have performed compared to their sector so far this year.

Brainsway (BWAY) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Improvement in depression scores, response and remission were all found to be comparable with standard Deep TMS in non-inferiority trial Improvement in depression scores, response and remission were all found to be comparable with standard Deep TMS in non-inferiority trial